HTB

COVID-19: vaccine research

Failure of mRNA vaccines to produce antibody responses in late diagnosed HIV with low CD4 count and high viral load

MHRA authorises Janssen/J&J COVID-19 vaccination in the UK

Reduced antibody responses to first dose of mRNA COVID-19 vaccines in HIV positive people with a lower CD4 count

France routinely recommends third dose of COVID-19 vaccine for some people with reduced immune function

US CDC reports 10,000 breakthrough infections after full vaccination: showing success of vaccine programme

Cases of COVID-19 reported including deaths in care home residents after full-course vaccination

Israeli study reports reduced vaccine efficacy in people with immune suppression until 14 days after the second dose

Novavax reports 43% efficacy against B.1.351 South African variant but negative impact in HIV positive participants

Oxford/AZ vaccine linked to 242 rare bloods clots in the UK: alternative recommended for people younger than 40

COVID-19 vaccine candidate from GSK and Sanofi to move to phase 3 placebo controlled study

Similar immune responses to the Oxford/AZ COVID vaccine reported In HIV positive and HIV negative participants

Low responses to mRNA COVID-19 vaccines in those older than 80 vs <60 years and in recipients of solid organ transplants

Two cases of viral breakthrough infections despite full protection from Pfizer mRNA vaccination

US post-authorisation safety data on Pfizer and Moderna vaccines

EMA review of Oxford/AZ vaccine and rare blood clots reported in the EU

Interim results report 80% efficacy for India’s COVAXIN vaccine

Three new COVID-19 vaccine studies enrolling in the UK

US phase 3 results enable FDA review of the Oxford/AstraZeneca vaccine

Janssen/J&J vaccine against COVID-19 is approved in the EU

HIV positive people in the UK now elligible for COVID vaccinations – and to become available at HIV clinics

What are the main COVID-19 variants? How can they affect vaccine responses?

Novavax: >90% efficacy in UK but 60% in South Africa, hints of lower effect in HIV positive participants

Russian Sputnik vaccine reports 91% efficacy at 21 days after the first dose

Janssen vaccine reports efficacy after single injection: FDA decision imminent

Oxford/AZ vaccine might still prevent severe COVID-19 from B.1.351 variant: supports continued used in South Africa

Unprecedented rapid speed of COVID vaccine development

WHO online vaccine tracker

COVID-19 vaccine pricing: a BBC guide

Pfizer COVID-19 vaccine might still overcome UK and SA variants

Novavax phase 3 vaccine study launched in the UK, South Africa, US, Mexico and Puerto Rico

Merck/MSD withdraws two vaccine candidates from further research but continues focus on treatment

Early safety and immune responses in older people using the Oxford vaccine: overall results complicated by dosing error

BHIVA statement on HIV positive people and access to COVID vaccines

Interim results report 94% efficacy with Moderna/NIH mRNA vaccine: FDA hearing on 17 December

HIV risk from some COVID-19 vaccines might be unlikely due to rarity of vector viruses involved

Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine

Oxford COVID vaccine enrolling HIV positive people at two London sites

US activists ensure people living with HIV can enrol in COVID-19 vaccine studies

HIV organisations oppose active-challenge COVID-19 vaccine studies

AVAC webinar with Barney Graham: COVID-19 vaccine targets, timelines, efficacy and ethical issues

Equitable access to vaccines against COVID-19

Vaccine candidates report phase 3 studies after early safety and immune responses in phase 1/2 studies

FDA guidance on COVID-19 vaccine includes minimal target of 50% efficacy

COVID-19 vaccine study opens for recruitment in UK

US NIH vaccine chief optimistic on prospects for SARS-CoV-2 vaccine

Sanofi and GSK collaborate on COVID-19 vaccine

Trial trackers for coronavirus vaccine studies